Abstract:Objective This study aimed to explore the efficacy of transarterial chemoembolization (TACE) combined with microwave ablation (MWA) adjuvant to lenvatinib and anti–PD–1 antibodies for patients with hepatocellular carcinoma (HCC). Methods A retrospective analysis of 67 patients with HCC treated at our hospital between October 2018 and May 2022 was conducted. All patients underwent a combination of TACE and MWA. Among them, 29 received postoperative treatment with molecular–targeted agents, like lenvatinib, along with anti–PD–1 antibodies such as sindilizumab, karelizumab, or tirilizumab. The remaining 38 patients did not receive postoperative systemic therapies, like targeted or immunotherapy. The survival and prognosis of all patients were analyzed. Results Nine patients in the observation group and 29 patients in the control group experienced recurrence, and the median progression–free survival 1 (PFS1) was not reached ‘Not Applicable’(NA) and 17.05 months (P=0.035), respectively. Failure to combine adjuvant therapy was identified as an independent risk factor for tumor recurrence, and the observation group had a 0.245 times lower risk of recurrence compared to that in the control group (P=0.005). Multivariable Cox regression analysis confirmed that the maximum tumor size, and tumor number were risk factors for tumor recurrence. Patients with a large maximum tumor size had a 1.519 times higher risk of recurrence compared to those with a small maximum tumor size (P=0.006), and patients with a large number of tumors had a 5.978 times higher risk of recurrence compared to those with a small number of tumors (P=0.02). The median PFS2 of the two groups was 11.795 and 21.257 months, respectively, though not statistically significant (P=0.955). However, there was a disparity in the percentage of BCLC stages associated with recurrence between the two groups. In the observation group approximately 22.22% of patients progressed to stage C, while in the control group, this proportion was 34.48%. The observation group exhibited a lower risk of distant metastasis compared to the control group. Conclusion Adjuvant treatment of HCC following TACE combined with MWA improved PFS and achieved better clinical outcomes compared to that with TACE combined with MWA alone.

Long-term Results and Prognostic Affecting Factors of Combined Interventional Therapies for Treatment of Intermediate and Advanced Primary Liver Cancer

Evaluation of the Efficacy for Alternated Treatment on Primary Liver Cancer by Interventional Therapy in Combination with Fractionated Stereotactic Conformal Radiotherapy

Effect of CT-Guided Microwave Ablation Combined with TACE on Liver Function and Survival of Patients with Primary Liver Cancer

Prognostic Factors for Survival after Transarterial Chemoembolization Combined with Microwave Ablation for Hepatocellular Carcinoma

Impact of Timing and Cycles of Systemic Chemotherapy on Survival Outcome of Colorectal Liver Metastases Patients Treated by Percutaneous Microwave Ablation

Prognostic factors affecting transarterial chemoembolization sequentially combined with percutaneous microwave coagulation therapy in treatment of hepatocellular carcinoma

Microwave Ablation Combined with Transarterial Chemoembolization Containing Doxorubicin Hydrochloride Liposome for Treating Primary and Metastatic Liver Cancers.

Transarterial Chemoembolization Combined with Microwave Ablation Versus Microwave Ablation Only for Barcelona Clinic Liver Cancer Stage B Hepatocellular Carcinoma: A Propensity Score Matching Study

Interventional oncological treatment of breast cancer liver metastasis (BCLM): single center long-term evaluation over 26 years using thermoablation techniques like LITT, MWA and TACE in a multimodal application

Clinical study on microwave ablation combined with transcatheter arterial chemoembolization in treating 46 cases of primary hepatocellular carcinoma

Microwave ablation in combination with TACE for the treatment of primary hepatic carcinoma

MWA Combined with TACE As a Combined Therapy for Unresectable Large-Sized Hepotocellular Carcinoma

Efficacy of Combining Ultrasonic with Three-Dimensional Imaging Guided Microwave Ablation in Treating Large Hepatocellular Carcinoma: a Comparative Study

High‐intensity focused ultrasound ablation combined with transcatheter arterial chemoembolization improves long‐term efficacy and prognosis of primary liver cancer

Safety and Effectiveness of Multi-Antenna Microwave Ablation-Oriented Combined Therapy for Large Hepatocellular Carcinoma

Evaluation of the efficacy of transarterial chemoembolization combined with microwave ablation followed by adjuvant therapy in patients with hepatocellular carcinoma

Ashort-termoutcomeanalysisoftransarterialchemoembolizationcombinedwith microwaveablationformultinodularhepatocellularcarcinoma

Large Primary Hepatocellular Carcinoma: Transarterial Chemoembolization Monotherapy Versus Combined Transarterial Chemoembolization‐percutaneous Microwave Coagulation Therapy

The Efficacy Of Transarterial Chemoembolization Combined With Microwave Ablation For Unresectable Hepatocellular Carcinoma: A Systematic Review And Meta-Analysis

Transarterial Chemoembolization and Sorafenib Combined with Microwave Ablation for Advanced Primary Hepatocellular Carcinoma: A Preliminary Investigation of Safety and Efficacy

[Prognostic Factors Influencing Survival in Patients with Large Hepatocellular Carcinoma Receiving Combined Transcatheter Arterial Chemoembolization and Radiotherapy].